On this page
Cord-derived cells are what most travelling patients actually receive, because they need no harvest and are ready when you arrive. Umbilical cord MSC therapy uses allogeneic cells from tissue donated after a normal birth — which removes one procedure, introduces a donor, and rests entirely on screening you cannot inspect.
Where the cells come from
After a normal delivery the umbilical cord and placenta are ordinarily discarded. With maternal consent, the cord can instead be processed to isolate mesenchymal stromal cells — most often from Wharton’s jelly, the connective tissue surrounding the cord vessels.
This is not the same as cord blood banking. Cord blood is collected from the vessels and is rich in blood-forming cells; cord tissue is the mesenchymal source. The two are routinely conflated and have different biology.
A 2026 meta-analysis in cerebral palsy had to separate them explicitly — distinguishing cord blood infusions from mesenchymal stromal cells — which is a good indication of how often they are treated as one thing.
See autologous versus allogeneic for the wider comparison.
Why this source is used so heavily
No harvest. For a patient flying in, that removes the largest scheduling obstacle — no liposuction, no marrow aspiration, no second procedure with its own recovery.
The cells are young. Donor age is effectively zero, which matters because MSC yield and proliferative capacity decline with the age and health of the donor.
Batches can be prepared and characterised in advance, making dose and quality more consistent than a preparation grown from whatever tissue a particular patient provided.
And it is available immediately, where autologous treatment means weeks of culture between harvest and injection. For someone travelling from another continent, that difference decides whether treatment is one trip or two.
What the human evidence covers
A randomised trial in knee osteoarthritis used cord-derived cells and compared dosing schedules, finding repeated dosing superior to a single dose — Umbilical Cord-Derived Mesenchymal Stromal Cells (MSCs) for Knee Osteoarthritis.
A prospective randomised controlled study examined cord MSC injection for diabetic foot ulcers — Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcer.
A 2025 systematic review and meta-analysis assessed MSC transplantation across autoimmune and rheumatic disease — Efficacy and safety of mesenchymal stromal cell transplantation in the treatment of autoimmune and rheumatic immune diseases.
A systematic review of controlled studies using cord blood for regenerative therapy identified structural barriers to assessing this literature at all — Systematic review of controlled clinical studies using umbilical cord blood for regenerative therapy.
Donor screening, which is the whole risk
Everything rests on work completed before you were involved. Maternal medical and travel history, infectious disease screening — hepatitis B and C, HIV, syphilis and others — and assessment of the delivery itself.
Then processing: isolation, expansion, characterisation against surface-marker criteria, and release testing for sterility, endotoxin and viability.
You cannot verify any of it by looking at a vial. What you can do is ask for it to be described, and notice whether the answer is specific.
This is the part of the offer where a clinic either has documentation or does not — see adverse events.
The immune question, stated properly
MSCs are often described as immune-privileged, meaning they express little of the machinery that would normally provoke rejection.
That is a simplification. Immune responses to allogeneic MSCs are described in the literature, and the question becomes sharper with repeated dosing, where a response to the first exposure could affect the second.
In practice serious rejection reactions are not a prominent feature of the trial safety data. But “immune-privileged” is a claim doing more work than the evidence supports, and it is worth hearing it as shorthand rather than as fact.
There is a related point about matching. Donor matching is not routinely performed for MSC therapy the way it is for organ or marrow transplantation, which is part of what makes an off-the-shelf product possible — and part of why the immune question has not been fully settled.
How it is given
Intra-articular injection for joints, which is what the osteoarthritis evidence used. Intravenous infusion for systemic indications. Local injection around a wound in the foot ulcer work.
Route governs which evidence applies. A trial injecting a knee tells you nothing about an infusion into a vein, even with the same cells from the same batch.
Cells are often cryopreserved and thawed before use, which is where viability losses occur — see MSC dosage research.
Fresh preparations avoid that loss and impose a scheduling constraint instead: the cells have to be ready on the day you are. Which of those a clinic offers usually reflects how its laboratory is organised rather than a clinical judgement about you.
Regulatory position
A donor-derived, culture-expanded product is unambiguously a manufactured biological rather than a patient’s own tissue returned to them, and most regulators treat it accordingly.
That is why availability differs so sharply between countries, and why the comparison with the United States is a comparison between a price and a prohibition rather than between two prices.
See regulation in Thailand and the US comparison.
Questions specific to cord-derived cells
These differ from the ones you would ask about your own cells.
- Cord tissue or cord blood — and which cells specifically?
- What maternal and infectious disease screening was done?
- Where were the cells expanded, and to what passage number?
- What release testing did this batch pass — sterility, endotoxin, viability?
- Fresh or cryopreserved, and what viability at the point of use?
See MSC therapy for the general picture.
Frequently asked questions
Whose cells am I getting?
A donor’s — from umbilical cord tissue donated after a normal delivery with maternal consent, then expanded in culture.
Is this the same as cord blood?
No. Cord blood is rich in blood-forming cells; cord tissue is the mesenchymal source. They have different biology and are routinely conflated.
Will my body reject them?
Serious rejection is not prominent in trial safety data, but “immune-privileged” is a simplification. Immune responses are described, particularly with repeat dosing.
Why use donor cells instead of my own?
No harvest procedure, no weeks of waiting, younger cells and more consistent batches. The trade is that you depend on screening you cannot inspect.
What evidence supports this?
Randomised trials in knee osteoarthritis and diabetic foot ulcers, plus a systematic review across autoimmune disease. Early evidence, not established practice.
How do I check the cells are what I am told?
You cannot verify it yourself. Ask for the screening and release testing to be described, and note whether the answer is specific or general.
Requesting a medical evaluation
Nothing on this page establishes whether any treatment is appropriate for you. That needs your history, your imaging and your current medications read by a clinician. If you would like that review, send your records and we will tell you honestly whether there is anything worth discussing — including when the answer is no.
This page is general information, not medical advice, and does not create a doctor–patient relationship. Regenerative treatments discussed here are in most cases investigational. Discuss any treatment with a clinician who knows your history.